The ETV6/RUNX1 (E/R) gene fusion is generated by the t(12;21) and found in approximately 25% of childhood B-cell precursor acute lymphoblastic leukemia. In contrast to the overwhelming evidence that E/R is critical for the initiation of leukemia, its relevance for the maintenance of overt disease is less clear. To investigate this issue, we suppressed the endogenous E/R fusion protein with lentivirally transduced short hairpin RNA in the leukemia cell lines REH and AT-2, and found a distinct reduction of proliferation and cell survival. In line with the observed concurrent inactivation of the phosphoinositide 3-kinase (PI3K)/AKT/ mammalian target of rapamycin (mTOR) pathway, pharmacological inhibition diminished the phosphorylation of AKT and ribosomal protein S6, and significantly increased the apoptosis rate in E/R-positive leukemias. Moreover, PI3K/mTOR inhibitors sensitized glucocorticoid-resistant REH cells to prednisolone, an observation of potential relevance for improving treatment of drug-resistant relapses. Of note, knockdown of the E/R fusion gene also severely impaired the repopulation capacity of REH cells in non-obese deficient/severe combined immunodeficient mice. Collectively, these data demonstrate that the E/R fusion protein activates the PI3K/AKT/mTOR pathway and is indispensible for disease maintenance. Importantly, these results provide a first rationale and justification for targeting the fusion gene and the PI3K/AKT/mTOR pathway therapeutically.
INTRODUCTION
The ETV6/RUNX1 (E/R) fusion gene (also known as TEL/AML1) is present in approximately 25% of childhood B-cell precursor acute lymphoblastic leukemia (BCP ALL) and represents the molecular equivalent of the t(12;21). 1 Despite an overall excellent initial treatment response, up to 20% of these cases relapse. 2 --4 The predominantly late occurrence of these relapses together with a considerable clonal variation between presentation and relapse implies that a postulated E/R-expressing (pre)leukemic sub-clone resists treatment and acquires distinct additional genomic aberrations during the secondary expansion and re-emergence. 5 --8 In contrast to the general notion that these relapses may be as treatment sensitive as the corresponding original leukemias, recent data from our group suggest that a substantial proportion of these cases fare poorly and may even qualify for stem cell transplantation. 5 Treatment intensification may overcome resistance in some cases, but will also increase the frequency of severe side and late effects. Particularly in such forms of leukemia, new treatment modalities that only target and exploit the relevant specific genetic defect are clearly needed.
Supported by ample evidence, the multi-step model of E/R-positive leukemia currently implies that the leukemia-initiating gene fusion occurs already in utero and is followed by several additional mutational hits before the disease becomes clinically evident. 9 Provided the chimeric protein is also required for the leukemia-replenishing process, as was suggested recently, both the specific molecular alteration itself as well as any affected signaling pathway components would constitute ideal targets for specific therapeutic attacks. 10 The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway senses and responds to mitogenic stimuli, energy and nutritional status, and thereby represents an essential regulator of many cellular processes such as protein synthesis, proliferation and apoptosis. Its constitutive activation in many forms of malignancies attests its pathogenetic importance. 11, 12 Consequently, a variety of small molecules have already been developed to therapeutically target specific pathway components. 13 Although T-cell precursor ALL seems to be the most frequent ALL form with a constitutive PI3K/AKT/mTOR pathway activation, only some of these cases resist therapy and consequently have a poor prognosis.
14 Despite an apparent lack of mutations in specific PI3K/AKT/mTOR pathway components in the vast majority of BCP ALL cases, analyses of gene expression data nevertheless suggest that the PI3K/AKT/mTOR pathway is also aberrantly activated in E/R-positive ALL. 15 --18 To investigate these preliminary observations further, we silenced the E/R fusion gene with a lentiviral vector transfer of fusion gene-specific short hairpin RNAs (shRNAs) into leukemia cell lines, studied the evoked effects on cellular functions and affected pathways in vitro and compared the in vivo malignant potential of untreated and treated cells in non-obese deficient/severe combined immunodeficient (NOD/SCID) mice.
MATERIALS AND METHODS

Cell culture
The E/R-positive BCP leukemia cell lines REH (DSMZ, Braunschweig, Germany) and AT-2 19 (kindly provided by JD Rowley, University of Chicago, Chicago, IL, USA), the E/R-negative BCP leukemia cell lines SEM, 697 and NALM6 (all DSMZ, Braunschweig, Germany) and primary leukemia blasts, obtained from bone marrow aspirations of children with ALL, were cultured as described previously. 20 In accordance with the Declaration of Helsinki, we obtained written informed consent from all patients' parents for using spare leukemia cells in this study. The study was approved by the ethical committees of the Children's Cancer Research Institute and St Anna Kinderspital. LY294002 (Calbiochem Corporation, San Diego, CA, USA) was used at 10 and 40 mM in cell lines and primary leukemias, respectively, and PI-103 21 (Selleck Chemicals, Houston, TX, USA) at 2 mM. Prednisolone (Solu-Dacortin, Merck, Whitehouse Station, NJ, USA) was added to the culture medium at 1 mg/ml for REH and SEM cells and at 10 mg/ml for NALM6 and 697 cells.
Immunoblotting
Cell lysates were prepared, resolved and transferred as described previously, 20 using 90 mg of total protein. Information on antibodies and protein detection is provided as Supplementary Information.
Assessment of protein phosphorylation
REH cells were kept overnight in serum-free medium before stimulation or in culture medium containing only 10% fetal calf serum, to assess induced and basal protein phosphorylation, respectively, before further processing. Further details can be found as Supplementary Information.
RNA interference
For E/R silencing, two sequences targeting the fusion region (Supplementary Figure S1) were used: shRNA A1 (5 0 -CACCGAATAGCAGAATGCATACTTCGAAA AGTATGCATCTGCTATT-3 0 ) has been described and tested previously, 10, 22 and shRNA G1 (5 0 -CACCGGGAGAATAGCAGAATGCATCGAAATGCATTCTGCTATTCT CCC-3 0 ) was newly designed to confirm and extend our previous data. 10 shRNA LacZ (Invitrogen, Carlsbad, CA, USA) was used as a non-targeting shRNA control. Lentiviral particles were generated as described in Supplementary Information. Transduced leukemic cells were selected for lentiviral integration with 5 mg/ml blasticidin (Invitrogen) for 2 weeks.
Quantitative real-time polymerase chain reaction Total RNA was isolated by Trizol reagent (Life Technologies, Carlsbad, CA, USA) and used for cDNA synthesis by SuperScript II Reverse Transcriptase (Invitrogen). RUNX1 and E/R transcripts were quantified by TaqMan real-time polymerase chain reaction using the ABI Prism 7900 Detection System (Applied Biosystems, Foster City, CA, USA). Published primer probe combinations were used for E/R and GUS as endogenous reference. 5, 23 RUNX1 mRNA levels were quantified by the following primer/probe combination: forward, 5 0 -CCTTCGTACCCACAGTGCTT-3 0 ; reverse, 5 0 -CAACG CCTCGCTCATCTT-3 0 ; and probe, 5 0 -TCTAGAGACGTCCACGATGCCA-3 0 .
Cell cycle, apoptosis and viability assays DNA synthesis and cell cycle distribution was determined by Click-iT 5-ethynyl-2 0 -deoxyuridine Flow Cytometry Assay (Invitrogen) according to the manufacturer's recommendations and analyzed using the FlowJo software (Tree Star, Ashland, OR, USA). The proportion of apoptotic cells was assessed by flow cytometry using Annexin-V/propidium iodide staining, and cleaved caspase 3 (BD-Pharmingen, Schwechat, Austria) staining after gating on the viable cell population based on light scatter characteristics. 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay was performed as described previously. 20 Gene expression profiling A detailed description on gene expression profiling is provided as Supplementary Information. Briefly, RNA from E/R-silenced REH and AT-2 cells was used for gene expression profiling on Affymetrix HG-U133-PLUS2 (Affymetrix, Santa Clara, CA, USA) 2 --3 weeks after transduction. Analyses were performed in R using Bioconductor packages, 24 with mean values of 5 biological replicates.
Leukemia xenograft experiments
A total of 5 Â 10 6 REH cells stably expressing either shRNA G1 or control shRNA were injected into the tail vein of NOD/SCID mice. Diseased animals were killed and bone marrow, spleen and liver analyzed for the presence of human leukemia cells by flow cytometry using anti-human CD19 (30-F11) and anti-mouse CD45 (4G7) antibodies (BD-Pharmingen). All animal experiments were approved by the Austrian Federal Ministry for Science and Research GZ:66.009/0065-II/10b/2009.
Statistical analysis
Differences between E/R-silenced and control cells were assessed by the paired two-tailed t-tests and between different model cell lines and various leukemias by the unpaired two-tailed t-tests. Statistical analysis of leukemia free survival of mice between groups was performed using log-rank test. P-values p0.05 were considered statistically significant.
RESULTS
Lentiviral-mediated transduction of E/R-directed
shRNA-expressing vectors silences the fusion gene Long-term suppression of E/R in the leukemia cell lines REH and AT-2 was achieved by a lentiviral transfer of shRNA-expressing vectors A1 and G1 that target different sequences of the E/R fusion transcript (Supplementary Figure S1 ). The respective cell lines were derived from E/R-positive relapse samples, express wild-type RUNX1 and lack the non-rearranged ETV6 gene. At 1 week after selecting the stable transfectants, both cell lines exhibited a substantial and constant reduction of E/R transcript and protein levels by approximately 50 --70% and 50 --80%, respectively, with merely minor variations between different experiments and cell lines (Figures 1a and b) . Of note, knockdown of the fusion gene did not repress wild-type RUNX1 expression Figure 1 . shRNA-mediated silencing of E/R in t(12;21)-positive leukemia cell lines. Leukemia cell lines REH and AT-2 were transduced with lentiviral constructs coding for shRNA A1 (A1) or G1 (G1) targeting E/R or a non-targeting shRNA control (C). Upon selection, expression of E/R and wild-type (wt) RUNX1 was quantified. Quantification of E/R (a) and RUNX1 (c) transcripts in biological replicates from REH and AT-2 (n ¼ 5) cells was determined in triplicates and normalized to endogenous GUS; **Pp0.01; ***Pp0.001 (paired t-test). Protein abundance of E/R (b) and RUNX1 (d) was detected by western blot analysis using anti-ETV6 and anti-RUNX1 antibodies, respectively. GAPDH was used as loading control. Numbers between bands represent the ratio between RUNX1 and GAPDH quantification. Data are representative of three independent E/R knockdown experiments. (Figures 1c and d) . With this standardized procedure, which satisfactorily suppressed E/R 2 --3 weeks after viral transduction, we were therefore able to evaluate the outcome of the respective depletion.
E/R suppression abrogates cellular proliferation and survival Regular cell counts revealed a gradual decrease of cellular growth down to 40 --50% in E/R-depleted vs control REH and AT-2 cell lines 2 week after selection, which subsequently stabilized for additional 3 --4 weeks (Figure 2a and data not shown). Growth suppression tended to be more pronounced with shRNA G1 compared with shRNA A1, most likely reflecting the differences in reduction of the fusion gene transcripts. Taking into account previous work that dealt with modulating effects of forced E/R expression on apoptosis, cell cycle and proliferation, 25 --28 we were especially keen to determine which of these systems would be predominantly de-regulated in our endogenous E/R knockdown model and responsible for the observed growth suppression. In line with our earlier observations that siRNA-induced fusion gene silencing augments apoptosis, 10 the proportion of early apoptotic cells in E/R-silenced cells also increased 1.5-to 3-fold ( Figure 2b ). In contrast to our expectations that E/R depletion would unleash the break from G1 to S transition and proliferation, 25 --28 E/R knockdown led to a distinct decline of proliferating cells (from a mean of 37% in controls to 24% in silenced cells) (Figure 2c ). Taken together with the cell cycle distribution showing a modest increase of the G0/G1 compartment in E/R-silenced cells (Figure 2d ), the decelerated proliferation rate can therefore be attributed to a G1 arrest with a concomitant increase in apoptosis at the transition to S that could account for the selective loss of the S phase. A possible effect of E/R suppression on the mitotic checkpoint function 29 was addressed by phospho-histone H3 staining, but did not reveal any differences between E/R-depleted cells and controls (5 --8% positivity in two independent E/R knockdown experiments; data not shown). These findings suggest that E/R silencing alters the growth pattern of the leukemia cell lines REH and AT-2 by impeding proliferation and survival. E/R suppression inhibits PI3K/AKT/mTOR activity To identify potential causes for the observed growth retardation, we compared the gene expression profiles from E/R-silenced REH and AT-2 cells with those obtained from shRNA control cells. This analysis suggested that PI3K/AKT/mTOR pathway is inhibited upon E/R knockdown. Since this signaling pathway is mainly regulated at the post-transcriptional level, we investigated whether E/R silencing affects protein phosphorylation of selected downstream substrates. E/R suppression reduced the cytokinemediated phosphorylation of AKT and ribosomal protein S6 (RPS6) by 50% and 30%, respectively, whereas phosphorylation of other key signaling proteins that are frequently altered in hematological malignancies 11 remained largely unaffected (Supplementary Figure S2) . The impaired phosphorylation of RPS6, a substrate of mTOR, is of specific interest, because this protein controls cell growth and proliferation through its regulation of protein synthesis, 30 and we therefore assume that the perturbation of these cellular effects is mediated by this pathway to at least some extent.
Pharmacological inhibition of PI3K/AKT/mTOR signaling affects survival and proliferation of E/R-positive leukemias To further investigate the influence of PI3K/AKT/mTOR signaling on proliferation and apoptotic processes in E/R-expressing leukemia cells, we compared first basal phosphorylation of PI3K and mTOR downstream effectors in REH cells upon E/R depletion with those of the pharmacological pan-PI3K family inhibitor LY294002 and the small-molecule dual PI3K/mTOR inhibitor PI-103. 21 LY294002 reduced phosphorylation of AKT and of RPS6 by 24% and 67%, respectively, in un-stimulated cells, which favorably compares with the 22 and 59% reduction that was achieved with E/R suppression. The small-molecule PI-103 Figure 2 . Suppression of E/R modulates cellular proliferation, survival and cell cycle distribution in leukemia cell lines. REH cells were subjected to shRNA-mediated silencing of E/R as described in Figure 1 . (a) Cell growth was assessed by regular cell counts after transduction and is depicted for REH cells expressing shRNA A1 or G1 in relation to shRNA control. Shown are means with standard deviation of four independent E/R knockdown experiments. inhibited phosphorylation of both proteins at a similar rate as the pan-PI3K inhibitor (AKT by 21% and RPS6 by 62%) (Figures 3a and b) .
Next, we tested whether PI3K/mTOR inhibitors are able to sensitize E/R-positive and, for comparison, also E/R-negative leukemia cell lines to prednisolone, a synthetic glucocorticoid that is widely used in ALL treatment regimens and to which E/R-positive relapse cases may become resistant. 3, 5 Cell death and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assays collectively demonstrate that exposure of GC-resistant REH cells to either one of the two inhibitors or prednisolone alone affects cellular viability and apoptosis rates in a comparable manner. A joint exposure, on the other hand, significantly augments the GC-induced apoptotic effect in particular with PI-103 (viability and apoptosis P ¼ 0.006 and 0.0004, respectively) ( Figure 3c ). E/R-negative leukemia cell lines, however, showed overall less distinct effects on inhibitor treatment and no sensitizing effect to GCs (Figure 3c) .
Finally, we investigated the potential clinical value of these findings by analyzing primary ALL samples. A 24-h exposure of BCP ALL cells---from children who had been consecutively enrolled in the current Austrian treatment protocol---to LY294002 significantly increased the apoptotic rate of E/R-expressing cells in comparison to E/R-negative controls (Figure 3d ). These data further support our notion that PI3K/AKT/mTOR signaling is aberrantly activated particularly in E/R-positive leukemias and that inhibition of this pathway could be a novel therapeutic option.
Silencing of E/R impairs engraftment of leukemia in a xenotransplant mouse model To address the functional consequences of E/R knockdown in vivo, we used differentially E/R-expressing REH cells in immunocompromized mice to investigate their repopulating capacity and ability to establish leukemia. We injected either E/R-silenced or control shRNA-expressing REH cells on day 15 after lentiviral transduction into the tail vein of NOD/SCID mice, which were then killed either when they exhibited clinical signs of disease or electively in week 27. Although all eight animals from the control group that had been transplanted with non-targeting shRNAinfected REH cells, died from human leukemia, only five of eight recipients of E/R-silenced REH cells developed leukemia. The three remaining animals neither developed leukemia nor showed any signs of leukemia infiltration at the end of the observation period. Strikingly, mice receiving E/R-depleted REH cells survived for 15 weeks (median, range 8 --15), whereas animals from the control group developed leukemia already 9 weeks (median, range 8 --10) after injection. Figure 4a shows a Kaplan --Meier plot indicating a significantly prolonged leukemia free survival of recipients of E/R-depleted cells. Light microscopy and flow cytometry confirmed the presence of human leukemia in the bone marrow (Figure 4b ) and peripheral blood and the dissemination of leukemia cells into the spleen irrespective of E/R silencing in diseased animals (data not shown). To monitor the long-term in vivo E/R repression effect, we quantified fusion transcripts from leukemias of xenografts that had received silenced REH cells. These experiments confirmed that the respective leukemias arose from E/R-repressed cells and that in vivo repression remains stable for a period that is comparable with that of in vitro cultured cells without blasticidin (Figure 4c ). These results provide first evidence that E/R expression essentially governs the repopulation capacity of leukemic REH cells and may thus be a critical factor for leukemia persistence in patients.
DISCUSSION
In continuation of our previous work, we investigated the longterm consequences of RNA interference-mediated E/R fusion gene silencing. 10 For this purpose, we used a lentiviral shRNA transduction system and vectors targeting the fusion site in cell lines that are accepted models for the respective types of leukemia because of their similar molecular make-up. 31 We found that suppression of the E/R fusion gene with specific shRNAs ablates the respective chimeric protein, slows down proliferation, promotes apoptosis and consequently leads to a profound reduction of treated cells. Yet, despite their propensity to undergo apoptosis, a significant proportion of E/R-depleted cells still can survive and continue to grow in vitro at a low stable rate for many weeks. On the molecular level, E/R knockdown impedes the PI3K/AKT/mTOR signal pathway, which is aberrantly activated in E/R-positive childhood leukemias. Of particular practical and clinical relevance is the fact that an identical effect can also be achieved with pharmacological pathway inhibition in both systems. An indispensable role of the E/R fusion gene for cell survival and continuous cell replenishment is further corroborated by a diminished in vivo repopulation capacity of E/R-suppressed REH cells in a xenotransplant NOD/SCID mouse model. In case these mice develop leukemia at all within 27 weeks, they did so significantly later than those receiving only mock-treated cells.
First preliminary evidence that experimental introduction of E/R fusion gene sequences into cells may activate their PI3K/AKT/ mTOR signaling pathway originally derives from transfected Ba/F3 cells (unpublished observation). Our E/R silencing experiments together with the analysis of published gene expression data (data not shown) confirm this finding, as we were able to prove that the aberrant activation of this particular pathway is a specific outcome of the E/R gene fusion and therefore exclusively confined to the affected type of BCP ALL also in the natural setting.
Conversely, the results of our experiments also preclude that any other type of genomic aberration, especially accompanying mutations of PI3K/AKT/mTOR pathway components, may be the cause of its constitutive activation. 11 As evidenced by the drug resistance and poor outcome of some T-cell precursor ALL cases with an activated PI3K/AKT/mTOR pathway, however, the extent of its activation as well as the ensuing biological effects are certainly also influenced by the particular cellular context in which they occur and are probably also modified by accompanying relevant mutations. 14 Apart from E/R's specific influence on the PI3K/AKT/mTOR signaling cascade, it is conceivable that it also enhances some upstream signaling components, such as the receptors for erythropoietin and the stem cell factor (KIT), which may further augment subsequent pathway effects. In a recent paper, we already demonstrated that upregulation of the receptors for erythropoietin concurs with a survival advantage of E/R-positive cells and PI3K/AKT pathway activation. 20 Whether KIT---based on its overexpression in E/R-positive leukemias and differential regulation upon E/R knockdowns 33 ---also plays a similarly prominent role in E/R-positive leukemias as it does in acute myeloid leukemia, mastocytosis and gastro-intestinal stromal tumors, still remains to be shown. However, first preliminary evidence suggests that this might indeed be the case was recently provided by the observation that at least RUNX1 can regulate KIT. 34, 35 In consideration of the central position that the PI3K/AKT/mTOR signaling cascade occupies in many cellular tasks that are especially critical for neoplastic behavior in general, 11, 36 it is very likely that, as implied by the results of our experiments, its aberrant activation is not only essential for initiation, but also for the maintenance of E/R-positive leukemias. This assumption is further supported by the specific expression signature of E/R-positive leukemias, which also suggests the involvement of other PI3K/AKT/mTOR-regulated processes, including above all cell adhesion and DNA damage response. 15, 37 Pharmacological inhibition of the aberrantly activated PI3K/AKT/mTOR pathway has emerged as one of the therapeutic options for overcoming drug resistance. 13 Although E/R-positive leukemias are in general highly treatment-sensitive at initial presentation, a substantial proportion of them apparently become drug-resistant when they relapse. 2, 5, 38 As a proof of principle, we show that in GC-resistant cells prednisolone sensitivity can be partially restored with PI3K/mTOR inhibition. In line with similar problems that are encountered in T-cell precursor ALL cases whose drug resistance results from activating mutations in particular PI3K/AKT/mTOR pathway components, we thus consider PI3K/mTOR inhibition as a potential, plausible and useful accessory therapeutic option for resistant E/R-positive ALL. 14 The significantly impaired repopulation capacity of E/R-silenced REH cells in a xenotransplant NOD/SCID mouse model---which renders them unable to reconstitute leukemia at all or at least only after a substantial delay---is also of utmost biological and clinical importance. These results again provide additional evidence that the E/R fusion gene is not only relevant for initiation, but also essential for sustaining the leukemic process, and that therefore disease regression can be achieved through knockdown of its activity. The idea that products of tumor-initiating mutated genes are subsequently also required for the continuation and maintenance of the neoplastic process is not restricted to E/R-positive leukemias. Based on similar observations in several other tumors and tumor cell lines, which experience comparable proliferation holdups and the propensity to undergo apoptosis, this phenomenon has also been labeled as oncogene addiction. 39 In contrast to a recent report, which suggested that except for a modest increase in the S-phase fraction and higher proliferation rate, E/R downregulation has no other discernable effect on cell behavior or gene expression, 40 all evidence presented herein implies otherwise and proves that E/R has to be added to the growing list of oncogenes that not only initiate, but also nourish the leukemia. 41 --43 In conclusion, we have provided evidence herein that E/R expression is critical for the survival and propagation of the respective leukemia cells in vitro and in vivo. These findings have important biological and clinical implications. Based on what is known so far, the E/R gene fusion is the earliest and most specific alteration in this type of leukemia. Therefore, the fusion gene together with its products provides a tremendously interesting therapeutic target, because one need not pay attention to the extreme sub-clone variegation encountered in the E/R-positive cell pool. 44 The fact that key components of the PI3K/AKT/mTOR signaling pathway, which is under the control of the respective fusion gene, constitute already pharmaceutically accessible elements should therefore be further exploited experimentally.
